PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
1.89M / 3.59M (Avg.)
-1.60 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-80.45%
Negative EBIT growth while CRN.AX is at 19.60%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-80.45%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
5682.20%
Net income growth above 1.5x CRN.AX's 47.33%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
5320.00%
EPS growth above 1.5x CRN.AX's 47.22%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
5326.67%
Diluted EPS growth above 1.5x CRN.AX's 47.31%. David Dodd would see if there's a robust moat protecting these shareholder gains.
4.50%
Slight or no buybacks while CRN.AX is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
4.34%
Diluted share change of 4.34% while CRN.AX is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
42.92%
OCF growth under 50% of CRN.AX's 11374.81%. Michael Burry might suspect questionable revenue recognition or rising costs.
-41.89%
Negative FCF growth while CRN.AX is at 113.93%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-100.00%
Negative 10Y revenue/share CAGR while CRN.AX stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-100.00%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
73.70%
OCF/share CAGR of 73.70% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
73.70%
Positive OCF/share growth while CRN.AX is negative. John Neff might see a comparative advantage in operational cash viability.
73.70%
Positive 3Y OCF/share CAGR while CRN.AX is negative. John Neff might see a big short-term edge in operational efficiency.
162.86%
10Y net income/share CAGR of 162.86% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
162.86%
Positive 5Y CAGR while CRN.AX is negative. John Neff might view this as a strong mid-term relative advantage.
162.86%
Positive short-term CAGR while CRN.AX is negative. John Neff would see a clear advantage in near-term profit trajectory.
-26.50%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-26.50%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-26.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.30%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
328.76%
We expand SG&A while CRN.AX cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.